(ACTU) Actuate Therapeutics - Ratings and Ratios

Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company specializing in the development of innovative cancer therapies. Its lead product candidate, Elraglusib Injection, is a glycogen synthase kinase-3 (GSK-3) inhibitor designed to target metastatic pancreatic ductal adenocarcinoma (PDAC). The company is also investigating Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. Formerly known as Apotheca Therapeutics, Inc., the company rebranded as Actuate Therapeutics, Inc. in October 2015. Headquartered in Fort Worth, Texas, Actuate Therapeutics was incorporated in 2015 and is focused on advancing its pipeline of precision oncology therapies.

The companys approach centers on leveraging its expertise in kinase inhibition to develop targeted therapies that address unmet medical needs in oncology. Elraglusib, its flagship candidate, has shown potential in preclinical and early clinical studies to inhibit tumor growth and enhance anti-tumor immunity. Actuate Therapeutics is committed to advancing Elraglusib through clinical development, with a focus on improving outcomes for patients with aggressive and hard-to-treat cancers.